12/10/2025
🚀 Vitruvian Shield SA Shield achieves Scientific Suitability Recognition from 🇵🇹
We’re proud to announce that Vitruvian Shield–PT LDA with headquarters at PCI · Creative Science Park Aveiro Region has been officially granted Scientific Suitability (Idoneidade Científica) recognition by the Agência Nacional de Inovação (ANI) — a key milestone in our journey to advance digital health, AI-driven research, and decentralized clinical trials.
This recognition, issued under Article 37-A of the Portuguese Investment Tax Code, validates Vitruvian Shield’s R&D capabilities in ICT applied to health, including:
💡 Remote patient monitoring (RPM)
💡 AI-enabled adaptive trial platforms
💡 Continuous digital biomarker discovery
💡 Integration of multi-sensor wearable technologies
It also opens the door to major national and European innovation instruments such as SIFIDE II, Portugal 2030, PRR Health Cluster, and Innosuisse co-funded research programs — reinforcing our mission to bridge clinical research and real-world healthcare through innovation.
We’re deeply grateful to ANI for their trust, and to our multidisciplinary teams in Switzerland, Portugal, and the UAE for their scientific rigor, technological excellence, and commitment to patient-centric innovation.
This milestone marks the next chapter of our expansion — enabling stronger academic and hospital partnerships, accelerating pilot studies in epilepsy, cardiology, diabetes, and oncology, and driving global regulatory readiness for our platform.
🌍 Together, we continue shaping the future of connected clinical research.